Nymox Pharmaceutical Corporation EPS Ratio 2011-2026 | NYMX

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Nymox Pharmaceutical Corporation

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-0.15	-0.16	-0.19	-0.18	-0.26	-0.28	-0.48	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-0.15	-0.48	-0.243

Quarterly EPS Ratio Nymox Pharmaceutical Corporation

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-0.03	-	-0.06	-0.04	-0.04	-	-0.04	-0.08	-0.04	-	-0.05	-0.04	-0.05	-	-0.09	-0.05	-0.06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-0.03	-0.09	-0.0515

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-15.4	-	2.43 %	$ 254 M	Germany
Aeglea BioTherapeutics AGLE	-24.9	-	-	$ 1.01 B	USA
I-Mab IMAB	-7.66	-	-	$ 866 M	China
Midatech Pharma plc MTP	-31	-	-18.52 %	$ 27.3 M	Britain
AIkido Pharma AIKI	-1.57	-	1.93 %	$ 17.4 M	USA
Aptorum Group Limited APM	-0.19	$ 0.9	-2.33 %	$ 6.62 M	China
Biophytis SA BPTS	-0.26	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	1.51	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	1.37	$ 21.96	-0.68 %	$ 3.64 B	USA
RedHill Biopharma Ltd. RDHL	-0.21	$ 1.02	-0.49 %	$ 428 M	Israel
Allakos ALLK	-2.14	-	-	$ 28.6 M	USA
Advaxis ADXS	-7.99	-	-9.65 %	$ 45.9 M	USA
AlloVir ALVR	-2.85	-	4.14 %	$ 49.1 M	USA
Ampio Pharmaceuticals AMPE	-10.7	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-3.25	-	-	$ 10.1 M	USA
Akouos AKUS	-2.52	-	0.23 %	$ 488 M	USA
Aligos Therapeutics ALGS	-2.45	$ 6.4	4.4 %	$ 63.3 M	USA
Applied Therapeutics APLT	-1.42	-	-	$ 8.42 M	USA
Aptinyx APTX	-0.96	-	-39.0 %	$ 4.57 M	USA
Aridis Pharmaceuticals ARDS	-1.62	-	17.91 %	$ 11.1 M	USA
Avenue Therapeutics ATXI	-0.93	-	-52.27 %	$ 4.45 M	USA
Amphastar Pharmaceuticals AMPH	2.1	$ 21.41	1.9 %	$ 1 B	USA
Aravive ARAV	-2.1	-	-13.39 %	$ 1.45 M	USA
AstraZeneca PLC AZN	0.08	-	-	$ 96.9 B	Britain
BioDelivery Sciences International BDSI	0.85	-	-4.8 %	$ 255 M	USA
Aeterna Zentaris AEZS	-0.07	-	5.93 %	$ 314 M	Canada
Brainstorm Cell Therapeutics BCLI	-1.11	-	-2.5 %	$ 5.88 M	USA
Kazia Therapeutics Limited KZIA	-0.186	$ 12.26	3.72 %	$ 1.62 B	Australia
AgeX Therapeutics AGE	-1.91	-	-10.17 %	$ 12.2 K	USA
BioNTech SE BNTX	42.2	$ 105.46	-0.09 %	$ 27.2 B	Germany
BeiGene, Ltd. BGNE	0.2	-	0.49 %	$ 251 B	Cayman-islands
Ayala Pharmaceuticals AYLA	-2.46	-	-	$ 7.46 M	Israel
Applied Genetic Technologies Corporation AGTC	-0.36	-	-	$ 26.5 M	USA
Aquestive Therapeutics AQST	-0.78	$ 4.08	0.25 %	$ 436 M	USA
Arcutis Biotherapeutics ARQT	-0.13	$ 23.26	1.75 %	$ 2.96 B	USA
Cara Therapeutics CARA	-2.46	-	-3.03 %	$ 260 M	USA
Autolus Therapeutics plc AUTL	-1.08	$ 1.44	-5.88 %	$ 383 M	Britain
Aptose Biosciences APTO	-10.4	-	-45.71 %	$ 1.2 M	Canada
BioXcel Therapeutics BTAI	-5.73	$ 1.06	-3.64 %	$ 12.9 M	USA
CASI Pharmaceuticals CASI	-0.27	-	-	$ 35.4 M	USA
AVROBIO AVRO	0.27	-	1083.1 %	$ 745 M	USA
Cabaletta Bio CABA	-2.1	$ 2.95	-3.28 %	$ 296 M	USA
Can-Fite BioPharma Ltd. CANF	-5.97	$ 2.91	-1.36 %	$ 4.79 M	Israel
bluebird bio BLUE	-1.93	-	-	$ 546 M	USA
CymaBay Therapeutics CBAY	-0.99	-	-	$ 3.45 B	USA
Akero Therapeutics AKRO	-3.75	-	-	$ 3.67 B	USA